Cargando…
Increased risk of disseminated cryptococcal infection in a patient with multiple sclerosis on fingolimod
Multiple sclerosis (MS) is the most common autoimmune disease of the central nervous system (CNS), with an estimated 2.3 million people being affected globally, and is a major cause of permanent disability. About 90 % of the affected patients with MS have relapsing-remitting type. Fingolimod became...
Autores principales: | Kaur, Pushpinder, Lewis, Alana, Basit, Abdul, Cyr, Nikolas St, Muhammad, Zaman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7516047/ https://www.ncbi.nlm.nih.gov/pubmed/32995275 http://dx.doi.org/10.1016/j.idcr.2020.e00961 |
Ejemplares similares
-
Disseminated Histoplasmosis in a Patient With Multiple Sclerosis
Treated With Fingolimod
por: Abrahamowicz, Aleksandra A., et al.
Publicado: (2021) -
Disseminated Cryptococcosis in a 63-year-old Patient with Multiple Sclerosis Treated with Fingolimod
por: Seto, Hiroyuki, et al.
Publicado: (2016) -
Cryptococcal Meningitis Reported With Fingolimod Treatment: Case Series
por: Del Poeta, Maurizio, et al.
Publicado: (2022) -
Primary cutaneous cryptococcal infection due to fingolimod – Induced lymphopenia with literature review
por: Patil, Sachin M., et al.
Publicado: (2020) -
Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)